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Summary.-Defects in cellular immunocompetence have been sought in 25 patients
with Kaposi's sarcoma. Skin tests with recall antigens, and PHA lymphocyte
stimulation in vitro showed that efferent delayed hypersensitivity responses are
intact in the majority. However, attempted sensitization and subsequent challenge
with DNCB demonstrated that the afferent limb of the responses was impaired in
some patients. This did not appear to be related to the morphology of the tumour
or to prognosis.
Tumour specific reactions were demonstrated both in vivo and in vitro and these
correlated significantly with the morphology and histology. The interpretation of
the results for an individual is confounded by the multiplicity of factors influencing
the outcome in a particular patient.
THE PIGMENTED haemangiosarcoma
first described by Kaposi in 1872 is a rare
malignant tumour, more prevalent in
equatorial Africa than in temperate areas
of the world. Though the restricted
geographical distribution may indicate an
inherited susceptibility to the tumour, it is
of interest that herpesviruses have been
located in long-term cultures of the sar-
coma. Their relevance to the aetiology
is as yet uncertain (Giraldo, Beth and
Haguenau, 1972). In adults, the disease
is primarily cutaneous but in children it
involves the lymph nodes, skin lesions
being uncommon (U.I.C.C., 1962).
The natural history of the disease is
variable and correlates with the gross
morphology and histology of the skin
tumour (Taylor et al., 1971a). Small
nodules are relatively benign and may
show spontaneous regression and disappear
(Lothe, 1963). Florid tumours are
exophytic and lack skin cover whereas
infiltrative lesions penetrate deeper tissues
and are associated with dense fibrosis,
but both are more aggressive than nodular
disease. The lymphadenopathic form is
disseminated and rapidly fatal.
Histologically, the diagnosis depends
on the recognition ofspindle cells, vascular
slits and vascular channels lined by endo-
lethial cells. In nodular and adenopathic
disease these elements are present in
equal proportions (mixed cell pattern). In
florid and infiltrative lesions, sheaves of
spindle cells predominate (monocellular
pattern). However, occasional tumours
show cellular pleomorphism and frequent
mitoses (anaplastic pattern) (Taylor et al.,
1 971a). Lymphocytes are commonly seen
in nodular and infiltrative lesions, both of
which are associated with a fibrotic
reaction.
Immunological studies of the sarcoma
in Uganda (Master et al., 1970) demon-
strated normalhumoralantibodyresponses
and immunoglobin levels in all patients.
However, a striking impairment of the
delayed cutaneous hypersensitivity res-
ponse to dinitrochlorobenzene (DNCB)
was noted in patients with " malignant "
(florid) tumours. In vitro studies (Taylor
et al., 1971b) also showed a correlation
between the gross tumour morphology
and the capacity of lymphocytes to be
stimulated in culture by phytohaemag-DELAYED CUTANEOUS HYPERSENSITIVITY REACTIONS IN PATIENTS
glutinin (PHA) or tumour cells. Whereas
transformation in response to PHA was
depressed in lymphocytes from patients
with florid tumours, a positive response
to both PHA and to mixed culture with
autologous tumour cells was noted in
lymphocytes from patients with nodular
or infiltrative tumours. These findings
led to the concept that the favourable
prognosis in patients with nodular disease
is associated with a delayed hypersensi-
tivity response to tumour, which is lacking
in those with florid disease.
MATERIALS AND METHODS
Patients admitted to the Uganda Cancer
Institute or Mulago Hospital between Sep-
tember 1969 and July 1970 with a clinical
diagnosis of Kaposi's sarcoma were all
potential participants in this study. Those
not studied withheld consent for the tests
or lacked sufficient tumour tissue for both a
diagnostic biopsy and preparation of cell
extracts. None had had chemotherapy in
the previous 2 years. On admission, the
patients underwent an extensive clinical
and radiological evaluation, and each had a
full blood count. The cutaneous tumours
were classified asnodular, florid orinfiltrative,
and also according to the Rules for Tumour
Classification (U.I.C.C., 1968). For subse-
quent therapy, the patients were randomized
as described by Vogel et al. (1971). The
clinical and research investigations were all
approved by a committee at Makerere
University Medical School.
Preparation of cell extracts-.Sterile tech-
niques were used throughout. Tumour tissue
was obtained at the time of diagnostic
biopsy. Where possible, an area of tumour-
free skin was excised for preparation of the
control extract, obtained as described by
Taylor et al. (1971b) but lymphocytes were
used ifsufficient skin was not available. The
method used to prepare the extracts has been
described in detail by Fass, Herberman and
Zeigler (1970). Cell suspensions were
obtained by mincing the tissue and cells
disrupted by freezing, and subsequent expo-
sure to saline solutions of decreasing tonicity.
After each hypotonic lysis, the suspension
was centrifuged and the supernatant fluid
collected and pooled. This was then concen-
trated over a 36-h period by pressure dialysis
at 4°C to a final volume of 1 ml. Following
preparation, the protein concentration of
the extracts was determined by the method
of Lowry et al. (1951). The extracts were
made up to 3 protein concentrations (1 mg/ml,
0 5 mg/nil and 0-1 mg/ml) divided into 1 ml
aliquots in tuberculin syringes and stored at
-70°C until testing. The preparations were
checked for bacteriological contamination
by blood agar culture before testing.
Administration and interpretation of the
skin tests.-Initial skin tests were undertaken
before chemotherapy. 0-1 ml of the follow-
ing antigens was injected intradermally in
that area of the back between the scapulae:
autologous tumour extract (ATE) and control
skin extract (ASE), intermediate strength
tuberculin (Parke, Davis, Detroit), mumps
skin test antigen (Eli Lilly & Co., Indiana),
Candida albicans (as Dermatophytin ' 0 "
1: 100, Hollister Steir Laboratories, Wash-
ington), brucella antigen (as Brucellergen
Protein Nucleate, Merke, Sharp and Dohme,
Pennsylvania) and streptokinase-strepto-
dornase (Lederle, New York). Skin tests
were read at 24 and 48 h by 2 individuals, one
of whom was unaware of the arrangement of
the injections. A positive test was defined
as one having induration of at least 5 mm in
diameter.
Skin punch biopsies were performed on all
positive tumour extract skin tests and cor-
responding control sites. Histological sec-
tions from these biopsies were reported
under code by an independent observer.
Perivascular mononuclear cell accumulations
at the site of ATE injection and not ASE,
were required for the test to be recorded as
positive.
Delayed hypersensitivity to DCNB (1-
chloro-2,4-dinitrobenzene, Eastman Chemi-
cals, New York) was tested using a 2000 ,ug
sensitizing dose, which was allowed to evapor-
ate within a 2 cm diameter polyethylene ring
applied to the right forearm. The area had
been previously cleaned with acetone and
was subsequently covered by an occlusive
dressing. Fourteen days later, a 100 ttg
challenge was applied to another site. This
was examined at 48 h and counted as positive
if induration, vesicles and bullae were
present.
Lymphocyte transformation by PHA and
tumour cells. Lymphocytes were cultured
from a sub-sample of the patients selected
only by availability of sufficient blood or
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tumour tissue, the techniques being those
fully described by Taylor et al. (1971b).
The cells were wsashed once with medium
RPM1 1640 (Gibco, N.Y., U.S.A.) and then
resuspended in this medium supplemented
with 200o gammaglobulin-free foetal calf
serum. Two ml ofthe suspension, containing
2 x 106 mononuclear cells was incubated
wNith PHA, autologous tumour cells, or control
lymphocytes which had been previously
inhibited by mitomycin C. Lymphocyte
transformation was estimated by measuring
the uptake ofiodo-uridine (1251) into lympho-
blasts, using a gamma spectrometer. The
results (Table I) are expressed as the ratio
of iodo-uridine in stimulated cultures: uptake
in control tubes. In the previous work a
tumour control uptake ratio of greater
than I 5 was regarded as positive evidence of
transformation induced by tumour cells.
RESULTS
The clinical features of the 25 patients
and the results of the immunological
evaluation are shown in Table I.
There was no correlation between
possible responses to these tests and classi-
fications ofthe tumours, based on U.I.C.C.
rules. The table is therefore subdivided
on the basis of gross tumour morphology.
Of25 patients skin tested with bacterial
antigens one or more positive recall
responses were seen in all but one (patient
No. 3). This man had an anaplastic,
florid tumour. Negative responses were
obtained to all the tests and he died of his
tumour, despite intensive chemotherapy.
The results of dinotrochlorobenzene
testing are shown in Table II, 12 of 25
patients having positive responses. This
proportion ofpositive : negative responses
was seen in patients with both florid and
nodular tumours, the few patients with
infiltrative or lymphadenopathic forms
responding less frequently. Of 9 patients
with less than 2 positive recall responses,
only 2 had a positive DNCB reaction,
whereas of 15 patients with 2 or more
positive recall responses, .9 had positive
DNCB tests (01 <P < 0.05).
No significant correlation was noted
between positive DNCB skin tests and
the skin response to ATE or lymphocyte
transformation induced by PHAortumour
cells. Ten of those with positive res-
ponses and 8 with negative DNCB skin
tests improved with chenmotherapy. Of
the 2 who died, one (No. 22) died of a
cardiovascular collapse unrelated to his
disease or therapy.
Bacteria were cultured from a number
of the primary tumours, but the ATE
and ASE were sterile in the 25 patients
listed in Table I. In a further 2 patients,
blood agar culture revealed bacterial
contamination and these were excluded
from the study. No immediate skin
reactions were noted, the induration
being maximal at 48 h. Positive res-
ponses were maximal at the 1 0 mg/ml
injection site, with the exception of that
of patient No. 14, in whom the 0 5 mg/ml
site had the greater diameter.
Perivascular mononuclear infiltrates
were observed in all of the positive ATE
skin test sites, with the exception of
patientNo. 13inwhom a micro-abscess was
demonstrated, and the test counted as
negative. Control (ASE or ALE) sites
were clinically negative, with the exception
of patient No. 19. However, the biopsy
TABLE II.-Incidence of Delayed Cutaneous Hypersensitivity to DNCB and Autologous
Tumouqr Extract (ATE) in Patients with Different Gross Tumour Morphology
Type of tlumou
Nodular
Infiltrative
Florid
Lympha(lenopathic
Total
DNCB
No. positive
per no. teste(l 00 positive
4/8 50
1/4 25
6/10 60
1/3 33
12/25
ATE
A
No. positive
per no. teste(1 % positive
5/8 63
2/4 50
1/9 11
0/3 0
8/24
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TABLE III.-Correlation ofthe Response to DNCB and Tutmour Extract with
Tnmou&r Histology
Tumour histology
Mixed cell
Monocellular
Anaplastic
Total
DNCB
No. positive
per no. tested % positive
7/14 50
4/8 63
1/3 30
12/25
ATE
, ~~~A
No. positive
per no. tested % positive
6/14 43
2/8 25
0/2 0
8/24
revealed no mononuclear infiltration and
the response to ATE has been regarded
as positive. Because of tumour induced
lymphocyte transformation in culture,
the skin test sites were also biopsied in
patientNo. 22. Both showedperivascular
mononuclear infiltrate, more marked at
the site ofATE.
Eight of 24 patients showed positive
results to ATE (Table II). Seven of
these were in patients with nodular or
infiltrative tumours but the frequency was
significantly lower in those with florid or
lymphadenopathic lesions (P < 0-025,
Fischer's exact test). There was also
correlation with the histology of the
tumour (Table III), the incidence of
positive results being greatest in those
whose tumours had a mixed cell pattern.
The duration of symptoms was greater
than a year in those with positive response
to ATE and all improved after chemo-
therapy. No correlation is seen between
positive responses to ATE skin tests and
in vitro tumour induced transformation.
However, in 4 of those with positive ATE
responses, the tumour nodules were too
small to provide sufficient cells for both
tests.
Only one patient (No. 9) with a florid
tumour showed apositive response to ATE
and on admission lymphocyte transforma-
tion was negative. His tumour responded
completely to chemotherapy and he was
re-tested on remission. The ATE skin
test was positive, as was PHA induced
transformation (ratio 129) and trans-
formation induced by the ATE used for
skin test (ratio 1-6).
DISCUSSION
Kaposi's sarcoma, in the majority of
adult Africans, is a distinctive clinical
entity but the tumour morphology may
be variable. Tedeschi (1958) believed that
a tumour changed its appearance as the
disease progressed, but Reynolds, Winkel-
mann and Soule (1965) described many
cutaneous forms and implied that each
retained its integrity during the course
of the disease. This concept was con-
firmed by Taylor et al. (1971a), who
found that differing histological patterns
correlated with the tumour morphology
(Table IV). Nevertheless, histological dif-
ferences were inadequate to explain the
variable outcome. " Benign " nodules
and the fatal lymphadenopathic form of
the disease both have a mixed cell histo-
pathology. The differing prognoses could
be explained by variation either oftumour
cell antigens or of the host response.
In the present study, the majority of
patients were able to exhibit delayed
hypersensitivity recall responses when
challenged with bacterial antigens. Only
one patient with an advanced florid
tumour was unresponsive to all antigens
and to DNCB sensitization. This con-
trasts with the findings of Solowey and
Rappaport (1965) that of 150 patients
with other cancers, 110 were anergic to
the test materials. The responses to
these intradermal injections, which test
only the effector mechanism, did not
correlate with the morphology ofKaposi's
sarcoma or the subsequent clinical course.
The reactions to DNCB were related
to tumour morphology and reflected to
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TABLE IV.-Summary of Types of Kaposi's Sarcoma
Cliical type
Nodular
Florid
Infiltrative
Lymphadlenopathic
Behaviour
Indlolent
Locally aggressive
Locally aggressive
Disseminate(d
Age group
(years)
Over 25
Over 25
Over 25
Under 25
Typical
histopathology
Mixed cell
Monocellular2
Monocellular
Mixed cell
Response to
chemotherapy1
Remission
Remission3
Refractory
Refractory
1 From Vogel et al (1971).
2 Anaplastic histopathology may also be seen in florid tumours.
3Anaplastic vaiiants are usuially refractoiy to treatment.
some degree the extent of reactivity to
recall antigens. As DNCB testing invoIx es
both the afferent and effector immune
processes, it appears that non-reactive
patients lack the capacity to be sensitized
to the synthetic antigen. It is not known
whether such a defect leads to, or results
from, dlevelopment of the tumour, and
Kaposi's sarcoma has been reported
following immunosuppressive therapy
(Siegel et al., 1969). The correlation
between tumour morphology and DNCB
sensitization was not as clearly defined,
as in a series of patients reported pre-
viously by Master et al. (1970) in which all
patients with nodular disease reacted to
DNCB. However, the morphology of the
principal tunmour was classified differently
in the 2 series and this may account for
some discrepancy. The 4 negative res-
ponses to DNCB in adults with nodular
disease may have been the result of
excessively critical criteria used in defining
a positive response in the present study,
as lvmphocyte transformation in response
to PHA was demonstrated in 2 of these
patients.
The little information available from
the in vitro studies w%Aith PHA confirms the
recall tests with bacterial antigens by
demonstrating the presence of competent
circulating lymphocytes in patients of
each clinical group. However, in lym-
phocytes from some patients, the response
to PHA is considerably impaired, and
similar results have been reported in
Hungarian patients by Dobozy et al.
(1973).
The skin reactions evoked bv auito-
logous tumouir extract (ATE) (lemons-
trated the clinical and histological features
of delayed hypersensitivity reactions.
Negative reactions to ATE did not result
from nonspecific cutaneous anergy, as
the majority of patients with negative
reactions had positive responses to recall
bacterial antigens and/or DNCB. The
antigens which evoked the positive res-
ponses to ATE appear to be tumour
specific, as negative responses were
recorded at the site of control injections.
The concept that skin reactivity to ATE
reflects the response to tumour antigen,
and not to contaminating bacterial pro-
ducts, is further supported in the present
work by the greater frequency of positive
responses in patients with nodular and
infiltrative tumours compared with other
types. While bacterial antigens would
be expected in greater concentration in
fungating lesions, the frequency ofpositive
responses to ATE were invariably associ-
ated with improvement after therapy
(Table I) but a negative test was not
predictive.
This study addsKaposi'ssarcomatothe
growing list of human tumours in which it
is possible to demonstrate specific cell
mediated immunity by cutaneous reacti-
vity to ATE. The majority of these
responses were evident in patients with
indolent tumours, and were invariably
associated with favourable responses of
the tumour to chemotherapy. However,
occasional responses to ATE were seen
in patients with florid or infiltrative
tumours.
This implies that the lack of reactivity
in the majority of patients with these
aggressive tumours is not entirely due to
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lack of antigens. It may, however,
reflect the interaction of humeral and
cellular immune mechanisms, a blocking
factor protecting the tumour from the
cellular immune response. A search for
such antibodies would be a logical exten-
sion ofthis study ofpatients with Kaposi's
sarconma.
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